While about one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes shingles, the risk of developing shingles can be up to two times higher in people with immunocompromising conditions compared to those without these conditions. Shingles is a viral infection that is caused by the reactivation of the varicella zoster virus, the same virus that causes chickenpox earlier in life. It can be a painful and potentially debilitating condition, and some people may also develop post-disease complications. From 1 September, the eligible population for Shingrix on the National Immunisation Program is expanding to cover more Australians aged 18 to 64 years who are considered to be at a moderate to high risk of shingles, due to an underlying condition and/or immunomodulatory/immunosuppressive treatments, as advised by the Australian Technical Advisory Group on Immunisation. Shingrix is a non-live vaccine. Non-live vaccines do not contain live viruses so they cannot replicate in the body and do not cause disease, even in people with weakened immune systems. Australian adults with immunocompromised conditions are encouraged to speak with their doctor or specialist for further information about their eligibility for the NIP funded shingles vaccine, and whether it is appropriate for them.